/
The terms we, us, our, Dar or the Company refer collectively to Dar Bioscience, Inc. and its wholly-owned subsidiaries, unless otherwise stated or the context otherwise requires. Unless otherwise stated, references to particular years, quarters, months or periods refer to our fiscal years ending December 31 and the associated quarters, months and periods of those fiscal years.
$1.96
+$0.02 (+1.03%)
EOD Jul 17, 2026
The business is unprofitable at the operating level (-1315.51% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 10429.4% YoY with margins expanding 238376.7pp. However, free cash flow softened 310%, worth monitoring whether this is timing or structural.
Free cash flow declined 310% versus the prior year, cash generation momentum has weakened. Negative free cash flow of -$10M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$1M
▲ +10429.4% YoY
Net Income (TTM)
-$12M
▼ -230.6% YoY
Op. Margin
-1034.38%
▲ +238376.7pp YoY
ROIC
-224.22%
▲ +1053.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$10M
▼ -309.6% YoY
Op. Cash Flow (TTM)
-$10M
▼ -280.6% YoY
Net Debt
-$17M
Net Cash Position
Cash & Equiv.
$19M
5Y CAGR: +6.1%
Continue Research
Dare Bioscience (DARE)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Dare Bioscience scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Dare Bioscience scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -1,034.4% operating margin and a -224.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh DARE's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.